| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | A Letai | |
| T Ni Chonghaile | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9 | Q22009407 | ||
| tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c | Q24290118 | ||
| PUMA, a novel proapoptotic gene, is induced by p53 | Q24291463 | ||
| Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis | Q24291662 | ||
| Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak | Q24296478 | ||
| Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins | Q24302494 | ||
| Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death | Q24311298 | ||
| bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death | Q24312157 | ||
| Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death | Q24312211 | ||
| Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
| bcl-w, a novel member of the bcl-2 family, promotes cell survival | Q24316822 | ||
| BID: a novel BH3 domain-only death agonist | Q24320091 | ||
| Hematopoietic malignancies demonstrate loss-of-function mutations of BAX | Q24321995 | ||
| Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3 | Q24324482 | ||
| Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 | ||
| BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents | Q24337209 | ||
| harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L) | Q24532147 | ||
| Bim: a novel member of the Bcl-2 family that promotes apoptosis | Q24532974 | ||
| miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 | ||
| MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2 | Q24563123 | ||
| Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members | Q24648909 | ||
| Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family | Q27645935 | ||
| X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death | Q27733156 | ||
| Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis | Q27734734 | ||
| The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex | Q28141249 | ||
| Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis | Q28144256 | ||
| BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis | Q28189945 | ||
| Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL | Q28200040 | ||
| p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa | Q28204059 | ||
| Puma is an essential mediator of p53-dependent and -independent apoptotic pathways | Q28213279 | ||
| A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow | Q28284105 | ||
| Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins | Q28284116 | ||
| Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells | Q28294137 | ||
| Induction of apoptosis by the Bcl-2 homologue Bak | Q28299871 | ||
| Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death | Q28363890 | ||
| Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model | Q28507750 | ||
| Integral role of Noxa in p53-mediated apoptotic response | Q28510421 | ||
| Enhanced phosphorylation of p53 by ATM in response to DNA damage | Q28609838 | ||
| Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane | Q28647586 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Induction of apoptosis in fibroblasts by c-myc protein | Q29614346 | ||
| Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane | Q29616354 | ||
| ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 | ||
| BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly | Q29617135 | ||
| Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics | Q29620467 | ||
| Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. | Q31929631 | ||
| 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Q33266778 | ||
| Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. | Q34139321 | ||
| BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells | Q34168023 | ||
| Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. | Q34358996 | ||
| Apoptosis: a link between cancer genetics and chemotherapy | Q34520432 | ||
| Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment | Q34773975 | ||
| Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). | Q34775350 | ||
| Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models | Q34783875 | ||
| Apoptosis-targeted therapies for cancer | Q35057060 | ||
| Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells | Q35153635 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis | Q36288687 | ||
| BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. | Q36445905 | ||
| TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer | Q37154117 | ||
| Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. | Q37554227 | ||
| Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins | Q39956386 | ||
| A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. | Q40007589 | ||
| The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin | Q40041107 | ||
| Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. | Q40150524 | ||
| Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma | Q40164619 | ||
| The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. | Q40178770 | ||
| A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. | Q40200783 | ||
| Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. | Q40497868 | ||
| Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). | Q40560044 | ||
| Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis | Q40694250 | ||
| bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia | Q41527925 | ||
| Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. | Q41714456 | ||
| Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. | Q41847989 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins | Q42608652 | ||
| Bcl-2 protects lymphoma cells from apoptosis but not growth arrest promoted by cAMP and dexamethasone | Q43766344 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells | Q46398403 | ||
| The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining | Q48375088 | ||
| Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. | Q53445992 | ||
| A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. | Q53595735 | ||
| Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. | Q55035703 | ||
| Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia | Q56268222 | ||
| Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas | Q69406382 | ||
| Bax mutations in cell lines derived from hematological malignancies | Q71519308 | ||
| Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells | Q73143423 | ||
| Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity | Q73574308 | ||
| Chromosomal and gene amplification in diffuse large B-cell lymphoma | Q74696857 | ||
| Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies | Q79370601 | ||
| Antiapoptotic BCL-2 is required for maintenance of a model leukemia | Q80591496 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S149-57 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Mimicking the BH3 domain to kill cancer cells | |
| P478 | volume | 27 Suppl 1 |
| Q38810868 | A NOXA/MCL-1 Imbalance Underlies Chemoresistance of Malignant Rhabdoid Tumor Cells |
| Q50074653 | A Non-apoptotic Function of MCL-1 in Promoting Pluripotency and Modulating Mitochondrial Dynamics in Stem Cells. |
| Q36740744 | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments |
| Q34979703 | A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma |
| Q37712188 | ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. |
| Q36081033 | AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations |
| Q39664189 | Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines |
| Q28484542 | Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma |
| Q28084243 | Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells |
| Q35237394 | An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance |
| Q35829855 | Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration |
| Q42061450 | Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors |
| Q34401490 | Anti-tumor activity of splice-switching oligonucleotides |
| Q36638317 | Apoptosis Activation in Human Lung Cancer Cell Lines by a Novel Synthetic Peptide Derived from Conus californicus Venom |
| Q37813468 | Apoptosis and aging: increased resistance to apoptosis enhances the aging process |
| Q37800273 | Apoptosis assays for quantifying the bioactivity of anticancer drug products |
| Q44448455 | Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells |
| Q38005914 | Apoptosis-modulating drugs for improved cancer therapy |
| Q30638314 | Apoptotic regulation of epithelial cellular extrusion |
| Q53684488 | BCL-2 as therapeutic target for hematological malignancies. |
| Q99564758 | BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models |
| Q35641404 | BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells. |
| Q39038331 | BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells |
| Q53244773 | BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma. |
| Q38643329 | BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. |
| Q60907777 | Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy |
| Q39690679 | Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death |
| Q64054793 | Bcl-x inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas |
| Q38626077 | Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. |
| Q64101953 | Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2 |
| Q38537879 | Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. |
| Q92570264 | Cancer Metabolism and the Evasion of Apoptotic Cell Death |
| Q90481728 | Cell-based high-throughput screen for small molecule inhibitors of Bax translocation |
| Q37713757 | Chemosensitization of prostate cancer by modulating Bcl-2 family proteins |
| Q37836936 | Chronic myeloid leukemia stem cells and developing therapies |
| Q36544778 | Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia |
| Q42121672 | Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. |
| Q38796648 | Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL |
| Q92592448 | Controlled induction and targeted elimination of p16INK4a-expressing chondrocytes in cartilage explant culture |
| Q47162016 | Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells |
| Q37613723 | Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma |
| Q39684441 | Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood |
| Q35153790 | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells |
| Q47653335 | Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition |
| Q39412943 | Effect of dual inhibition of apoptosis and autophagy in prostate cancer |
| Q90117810 | Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma |
| Q38207707 | Emerging drugs and combination strategies for basal cell carcinoma |
| Q33536938 | Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective |
| Q34334492 | Expression of Bim, Noxa, and Puma in non-small cell lung cancer |
| Q38094830 | Flow cytometry based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release |
| Q39583438 | GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy |
| Q30454476 | HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines. |
| Q38132855 | Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers |
| Q38615890 | How does metabolism affect cell death in cancer? |
| Q35221460 | Hox and a newly identified E2F co-repress cell death in Caenorhabditis elegans |
| Q39577806 | Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. |
| Q38946207 | Imaging cellular distribution of Bcl inhibitors using small molecule drug conjugates |
| Q39672272 | Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells |
| Q38957684 | Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics |
| Q27005947 | Ion channels and apoptosis in cancer |
| Q33924886 | Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1 |
| Q35524250 | Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia |
| Q64055535 | KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib |
| Q38860996 | Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737. |
| Q37500162 | Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma |
| Q36412836 | Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress |
| Q35156829 | Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death |
| Q37677213 | MAC and Bcl-2 family proteins conspire in a deadly plot |
| Q36706340 | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex |
| Q30502341 | MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents |
| Q35894198 | MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition |
| Q38115574 | Manipulating the apoptotic pathway: potential therapeutics for cancer patients |
| Q34135298 | Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199 |
| Q28072669 | Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer |
| Q55400384 | MicroRNA-644a promotes apoptosis of hepatocellular carcinoma cells by downregulating the expression of heat shock factor 1. |
| Q28069552 | Mitochondrial apoptosis and BH3 mimetics |
| Q38542765 | Mitochondrial targeted peptides for cancer therapy |
| Q34608671 | Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members |
| Q36703351 | Nanotechnology inspired tools for mitochondrial dysfunction related diseases |
| Q39569634 | Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells |
| Q38936710 | Novel Approaches to Apoptosis-Inducing Therapies |
| Q26782270 | Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy |
| Q28383663 | Novel non-AR therapeutic targets in castrate resistant prostate cancer |
| Q34793542 | Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. |
| Q38987827 | Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells |
| Q37983083 | Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms |
| Q41969196 | Overcoming EMT-driven therapeutic resistance by BH3 mimetics |
| Q37738894 | PAR-4 as a possible new target for pancreatic cancer therapy |
| Q33957511 | PINT: Pathways INtegration Tool. |
| Q37121933 | PUMA and BIM are required for oncogene inactivation-induced apoptosis. |
| Q35676278 | Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline. |
| Q39413018 | Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. |
| Q34374169 | Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry |
| Q39461469 | Regulation of cell death in cancer-possible implications for immunotherapy |
| Q35161624 | Regulation of the DNA damage response by ubiquitin conjugation |
| Q37512209 | Regulation of the autophagic bcl-2/beclin 1 interaction. |
| Q46029936 | Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent. |
| Q36386428 | Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives |
| Q35125250 | SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters |
| Q39148654 | Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing |
| Q35802945 | Selective peptide inhibitors of antiapoptotic cellular and viral Bcl-2 proteins lead to cytochrome c release during latent Kaposi's sarcoma-associated herpesvirus infection. |
| Q24337757 | Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy |
| Q33576187 | Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells |
| Q37773789 | Still embedded together binding to membranes regulates Bcl-2 protein interactions. |
| Q92941579 | Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia |
| Q37284895 | Structural properties of non-traditional drug targets present new challenges for virtual screening |
| Q36390326 | Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression |
| Q26783195 | Targeted Therapies in Adult B-Cell Malignancies |
| Q39706185 | Targeting Bcl-2-mediated cell death as a novel therapy in pancreatic cancer |
| Q36990787 | Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. |
| Q27011870 | Targeting Mcl-1 for the therapy of cancer |
| Q90047057 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer |
| Q38814114 | Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax |
| Q91286578 | Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors |
| Q26866936 | Targeting the Bcl-2 family for cancer therapy |
| Q37825614 | Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. |
| Q38191794 | Targeting tumour-supportive cellular machineries in anticancer drug development |
| Q38104439 | That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. |
| Q33997669 | The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma |
| Q61797351 | The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme |
| Q26827928 | The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma |
| Q89777571 | The role of targeted therapy in the management of patients with AML |
| Q49989306 | The role of targeted therapy in the management of patients with AML. |
| Q35975387 | The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors |
| Q37688303 | The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition |
| Q38084287 | Therapeutic targets in triple negative breast cancer |
| Q38798849 | To Prime, or Not to Prime: That Is the Question |
| Q30397851 | Ultra-High-Throughput Screening of Natural Product Extracts to Identify Proapoptotic Inhibitors of Bcl-2 Family Proteins. |
| Q35652832 | Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling |
| Q36747304 | pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737 |
Search more.